Regulation - Janssen

Filter

Current filters:

Janssen

Popular Filters

51 to 64 of 64 results

Johnson & Johnson units file for new Zytiga use in USA and EU

18-06-2012

Janssen Research & Development, a subsidiary of US drugs giant Johnson & Johnson (NYSE: JNJ), has submitted…

EuropeJanssenJohnson & JohnsonNorth AmericaOncologyPharmaceuticalRegulationZytiga

Janssen files NDA with FDA for canagliflozin in type 2 diabetes

01-06-2012

Janssen Research & Development, a subsidiary of health care giant Johnson & Johnson (NYSE: JNJ) has submitted…

canagliflozinDermatologicalsJanssenJohnson & JohnsonMitsubishi TanabeNorth AmericaPharmaceuticalRegulation

UK's NICE does U-turn, recommending Zytiga as Janssen cuts price

16-05-2012

UK drugs watch dog the National Institute for Health and Clinical Excellence (NICE) has reversed an earlier…

EuropeJanssenJohnson & JohnsonOncologyPharmaceuticalPricingRegulationZytiga

News briefs on Janssen, Bayer and Merck KGaA/Threshold

12-04-2012

In the USA, the Arkansas jury found that the Janssen unit of US health care giant Johnson & Johnson (NYSE:…

BayerFinancialJanssenJohnson & JohnsonLegalMerck KGaAPharmaceuticalRegulationRisperdalThreshold PharmaceuticalsXarelto

Strong results for Bayer's Xarelto in treating pulmonary blood clots

27-03-2012

German drugs and crops sciences group Bayer (BAY: DE), and partner Janssen, part of US health care major…

BayerCardio-vascularJanssenJohnson & JohnsonPharmaceuticalRegulationResearchRespiratory and PulmonaryXarelto

Bayer and J&J’s Xarelto gets US Priority Review for new indication

29-02-2012

The US Food and Drug Administration has granted Priority Review designation to the supplemental New Drug…

BayerCardio-vascularJanssenJohnson & JohnsonNorth AmericaPharmaceuticalRegulationXarelto

NICE issues negative guidance for Zytiga

02-02-2012

UK drugs watchdog the National Institute for Health and Clinical Excellence (NICE) has issued new draft…

EuropeJanssenJohnson & JohnsonOncologyPharmaceuticalPricingRegulationZytiga

Germany’s IQWiG sees added benefits for Incivo

24-01-2012

In an early benefit assessment pursuant to Germany’s Act on the Reform of the Market for Medicinal…

Anti-viralsEuropeIncivekIncivoJanssenJohnson & JohnsonPharmaceuticalPricingRegulationVertex

51 to 64 of 64 results

Parexel

Parexel

Back to top